Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank
Mandate

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

July 18, 2025 Banking and Finance

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).

The financing is structured as a venture debt loan – a form of growth financing tailored to innovative companies. It is provided under the InvestEU programme, which supports the EU’s green transition and efforts to spur innovation, industrial resilience and sustainable economic growth. The EIB financing will support development and commercialization of a fiber-based technology developed by PulPac as an alternative to single-use plastics.

The Vinge team consisted of Kristian Ford (responsible partner), Henrik Ossborn and Agaton Lindgren (banking and finance).

Read more in the press release from PulPac

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025